From the Journals

From the Journals

Few DLBCL patients benefit from nivolumab

Just 10 of 121 patients responded to nivolumab in a phase 2 trial and researchers aren’t sure why this particular group of patients responded.

From the Journals

Pembrolizumab extends Merkel cell PFS, OS

Patients with both Merkel cell carcinoma subtypes had significantly better survival with first-line pembrolizumab, compared with historical...

Pages